AMENDMENTS TO THE CLAIMS

1. (Original) A chimera adenovirus type 5/type 11 or type 35 vector which comprises a replication-defective adenovirus type 5 and a gene coding for a human immunodeficiency virus (HIV) envelope protein or for a mutant thereof equivalent in function thereto as integrated in said adenovirus type 5 in a manner capable of expression, with the fiber protein-encoding gene of said adenovirus type 5 being substituted by a gene coding for the fiber protein of an adenovirus type 11or type 35 or for a mutant thereof equivalent in function thereto in a manner capable of expression.

2. (Original) The chimera adenovirus type 5/type 11 or type 35 vector according to Claim 1, with a gene coding for a HIV clade B or HIV claid C envelope protein or for a mutant thereof equivalent in function thereto as integrated in a manner capable of expression.

3. (Currently amended) The chimera adenovirus type 5/type 11 or type 35 vector according to Claim 1 ~~or 2~~ which further comprises an HIV gag gene or a mutant gene thereof equivalent in function thereto as integrated therein in a manner capable of expression, together with said gene coding for HIV envelope protein or mutant thereof equivalent in function thereto.

4. (Currently amended) The chimera adenovirus type 5/type 11 or type 35 vector according to ~~any of Claims~~ claim 1 ~~to 3~~, with the fiber protein-encoding gene of said adenovirus type 5 being substituted by a gene coding for the fiber protein of an adenovirus type 35 or for a mutant thereof equivalent in function thereto in a manner capable of expression.

5. (Currently amended) The chimera adenovirus type 5/type 11 or type 35 vector according to ~~any of Claims~~ claim 1 ~~to 4~~, wherein the replication-defective adenovirus type 5 is an El-deficient, replication-defective adenovirus type 5 or an El and E3-deficient replication-defect adenovirus type 5.

6. (Currently amended) A pharmaceutical composition which comprises, as an active

ingredient, the chimera adenovirus type 5/type 11 or type 35 vector according to ~~any of claims~~ claim 1 ~~to 5~~.

7. (Original) The pharmaceutical composition according to Claim 6 which is to be used for the protection against HIV infection.

8. (Currently amended) The pharmaceutical composition according to ~~Claims~~ claim 6 ~~or 7~~ which is an HIV vaccine.

9. (Currently amended) The pharmaceutical composition according to ~~any of Claims~~ claim 6 ~~to 8~~ which is to be used in combination with a replication-defective virus vector or nonvirus vector comprising a gene coding for an HIV envelope protein or for a mutant thereof equivalent in function thereto as integrated therein in a manner capable of expression.

10. (Currently amended) The pharmaceutical composition according to ~~any of Claims~~ claim 6 ~~to 8~~ which is to be used in combination with an anti-HIV agent.

11. (Original) The pharmaceutical composition according to Claim 10, wherein the anti-HIV agent comprises at least one species selected from among reverse transcriptase inhibitors and protease inhibitors.

12. (Currently amended) A method for the protection against HIV infection or vaccination against HIV which comprises administration of the chimera adenovirus type5/type 11 or type 35 vector according to ~~any of Claims~~ claim 1 ~~to 5~~ and a replication-defective virus vector or nonvirus vector comprising a gene coding for an HIV envelope protein or for a mutant thereof equivalent in function thereto as integrated therein in a manner capable of expression.

13. (Currently amended) A method for the protection against HIV infection or vaccination against HIV which comprises administration of the chimera adenovirus type 5/type 11or type 35 vector according to ~~any of Claims~~ claim 1 ~~to 5~~ and an anti-HIV agent.